Items Tagged with 'GLP-1 receptor agonists'

The IFT FIRST Annual Event and Expo returns to Chicago from July 12-15, showcasing innovations in food science. This year features scientific programming within the expo hall, Ignite Sessions for professional development, and keynotes addressing pressing industry challenges.

Welcome to Dairy Foods' first Health and Wellness issue, focusing on dairy's revival, particularly cottage cheese and yogurt. Delve into recent trends, consumer preferences, and insights from industry reports, highlighting how dairy is adapting to meet the evolving needs of today’s health-conscious consumers.

The launch follows the FDA’s clarification that tagatose no longer needs to be declared as an added sugar, expanding use of the ingredient in reduced-sugar and better-for-you formulations.

Matt Graziose, Ph.D., Vice President of Regulatory Compliance at Chobani, joins Dairy Foods for Episode 65 of the “Let’s Talk Dairy” podcast to discuss protein and natural ingredients.

A recent survey reveals that U.S. adults prioritizing metabolic health are shifting their diets, focusing on healthier choices over aesthetics. With an emphasis on snacking smarter and the impact of GLP-1 medications, the dairy industry has a significant opportunity to meet evolving consumer needs.

Jacqueline Van Schaik, global lead nutritionist, Fonterra, joins Dairy Foods for episode 64 of the “Let’s Talk Dairy” podcast. During this podcast, she discusses GLP-1s and dairy.

The new Extra Creamy buttery blend is crafted with 8% fresh cream that delivers an ultra-smooth, luxuriously thick texture and a mild buttery flavor, the company said.

Amazon’s new health programs spotlight rising demand for personalized nutrition. As gut microbiome science advances, interest in pre-, pro- and postbiotics grows—positioning dairy as a convenient, nutrient-rich solution for digestive, metabolic, and overall health.

Foundayo will be available via LillyDirect, with prescriptions accepted immediately and shipping beginning April 6, followed shortly after by broad availability through U.S. retail pharmacies and telehealth providers, the company said.